Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea

American Journal of Gastroenterology

Volumn 112, Issue 2, 2017, Pages 365-374

  Cash, Brooks D ^a   Lacy, Brian E ^b   Schoenfeld, Philip S ^c   Dove, Leonard S ^d   Covington, Paul S ^d  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ALLERGAN PLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ELUXADOLINE; GABAPENTIN; MEVINOLIN; OMEPRAZOLE; PLACEBO; PSYLLIUM HYDROCOLLOID; SERTRALINE; TEMAZEPAM; TRIACYLGLYCEROL LIPASE; URSODEOXYCHOLIC ACID; DELTA OPIATE RECEPTOR; GASTROINTESTINAL AGENT; IMIDAZOLE DERIVATIVE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; PHENYLALANINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ALCOHOL CONSUMPTION; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; BRONCHITIS; CLINICAL EVALUATION; COLON ISCHEMIA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIVERTICULITIS; DIZZINESS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; GALLBLADDER; GASTROENTERITIS; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INFLUENZA; IRRITABLE COLON; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; OSTEOARTHRITIS; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RHINOPHARYNGITIS; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; SINUSITIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VATER PAPILLA STENOSIS; VOMITING; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; MUSCLE SPASM; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ABDOMINAL PAIN; ADULT; AGED; CONSTIPATION; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMIDAZOLES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; NAUSEA; PANCREATITIS; PHENYLALANINE; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SPASM; SPHINCTER OF ODDI DYSFUNCTION;

EID: 85001574648     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.542     Document Type: Article

References (55)

1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015; 313: 949-58.
2. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71-80.
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
4. Quigley EM, Abdel-Hamid H, Barbara G et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 356-66.
5. Su AM, Shih W, Presson AP et al. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil 2014; 26: 36-45.
6. Spiegel B, Harris L, Lucak S et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009; 104: 1984-91.
7. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004; 10: 299-309.
8. Paré P, Gray J, Lam S et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 2006; 28: 1726-35.
9. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology 2009; 136: 376-86.
10. Agarwal N, Spiegel BM. The Effect of irritable bowel syndrome on healthrelated quality of life and health care expenditures. Gastroenterol Clin North Am 2011; 40: 11-19.
11. US Food and Drug Administration. Lotronex. Highlights of prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021107s016lbl.pdf, 2010. Accessed on 5 May 2015.
12. US Food and Drug Administration. Xifaxan. Highlights of prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/021361s012lbledt.pdf, 2015. Accessed on 17 July 2015.
13. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrheapredominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
14. Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-70.
15. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
16. Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014; 109 (Suppl 1): S2-S26.
17. Marcus SN, Heaton KW. Irritable bowel-type symptoms in spontaneous and induced constipation. Gut 1987; 28: 156-9.
18. Nassif A, Oswald S, Kühn J-P et al. Loperamide-induced constipation in healthy subjects-an experimental model to evaluate the anti-constipation Effect of methylnaltrexone. Br J Clin Pharmacol 2011; 72 (Suppl.1): 23.
19. De Schepper HU, Cremonini F, Park MI et al. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16: 383-94.
20. Wade PR, Palmer JM, McKenney S et al. Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/μ opioid receptor antagonist. Br J Pharmacol 2012; 167: 1111-25.
21. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009; 155: 11-17.
22. Dove LS, Lembo A, Randall CW et al. Eluxadoline benefts patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013; 145: 329-38.
23. Lembo AJ, Lacy BE, Zuckerman MJ et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016; 374: 242-53.
24. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
25. Yaghoobi M, Romagnuolo J. Sphincter of Oddi dysfunction: updates from the recent literature. Curr Gastroenterol Rep 2015; 17: 31.
26. Banks PA, Bollen TL, Dervenis C et al. Classifcation of acute pancreatitis-2012: revision of the Atlanta classifcation and defnitions by international consensus. Gut 2013; 62: 102-11.
27. US Food and Drug Administration. Guidance for industry: drug-induced liver injury-premarketing clinical evaluation. Available at http://www.fda. gov/downloads/Drugs/../Guidances/UCM174090.pdf, 2009. Accessed on 7 September 2016.
28. Shaffer EA. Gallbladder sludge: what is its clinical signifcance? Curr Gastroenterol Rep 2001; 3: 166-73.
29. Meleine M, Matricon J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol 2014; 20: 6725-43.
30. Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol 2014; 2: 17-21.
31. Howaizi M, Sbaï-Idrissi MS, Baillet P. Loperamide-induced acute pancreatitis. Gastroenterol Clin Biol 2000; 24: 589-91.
32. Vidarsdottir H, Vidarsdottir H, Moller PH et al. Loperamide-induced acute pancreatitis. Case Rep Gastrointest Med 2013; 2013: 517414.
33. Badalov N, Baradarian R, Iswara K et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5: 648-61.
34. Barreto SG, Tiong L, Williams R. Drug-induced acute pancreatitis in a cohort of 328 patients. A single-centre experience from Australia. JOP 2011; 12: 581-5.
35. Hastier P, Longo F, Buckley M et al. Pancreatitis induced by codeine: a case report with positive rechallenge. Gut 1997; 41: 705-6.
36. Hastier P, Buckley MJ, Peten EP et al. A new source of drug-induced acute pancreatitis: codeine. Am J Gastroenterol 2000; 95: 3295-8.
37. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39: 709-16.
38. Turkmen S, Buyukhatipoglu H, Suner A et al. Prior cholecystectomy predisposes to acute pancreatitis in codeine-prescribed patients. Int J Crit Illn Inj Sci 2015; 5: 114-5.
39. Helm JF, Venu RP, Geenen JE et al. Effects of morphine on the human sphincter of Oddi. Gut 1988; 29: 1402-7.
40. Behar J, Biancani P. Neural control of the sphincter of Oddi. Physiologic role of enkephalins on the regulation of basal sphincter of Oddi motor activity in the cat. Gastroenterology 1984; 86: 134-41.
41. Tune A, Jivegård L, Pollard H et al. Location of enkephalinase and functional Effects of [Leu5]enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin Sci (Lond) 1992; 82: 169-73.
42. Patch GG, Morton KA, Arias JM et al. Naloxone reverses pattern of obstruction of the distal common bile duct induced by analgesic narcotics in hepatobiliary imaging. J Nucl Med 1991; 32: 1270-2.
43. Tompson DR. Narcotic analgesic Effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol 2001; 96: 1266-72.
44. Steinberg WM, Salvato RF, Toskes PP. The morphine-prostigmin provocative test-is it useful for making clinical decisions? Gastroenterology 1980; 78: 728-31.
45. Mossberg SM, Bloom A, Berkowitz J et al. Serum enzyme activities following morphine. A study of transaminase and alkaline phosphatase levels in normal persons and those with gallbladder disease. Arch Intern Med 1962; 109: 429-37.
46. Roberts-Tomson IC, Pannall PR, Toouli J. Relationship between morphine responses and sphincter of Oddi motility in undefned biliary pain after cholecystectomy. J Gastroenterol Hepatol 1989; 4: 317-24.
47. Luman W, Williams AJK, Pryde A et al. Influence of cholecystectomy on sphincter of Oddi motility. Gut 1997; 41: 371-4.
48. US Food and Drug Administration. Viberzi. Highlights of prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/206940s000lbl.pdf, 2015. Accessed on 17 July 2015.
49. Nathwani RA, Kumar SR, Reynolds TB et al. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol 2005; 100: 295-8.
50. Kagaya T, Takebe T, Koizumi M et al. Effect of long term alcohol feeding on the pancreas in rat. Gastroenterol Jpn 1979; 14: 327-35.
51. Pandol SJ, Raraty M. Pathobiology of alcoholic pancreatitis. Pancreatology 2007; 7: 105-14.
52. Shahedi K, Pandol SJ, Hu R. Oxidative stress and alcoholic pancreatitis. J Gastroenterol Hepatol Res 2013; 2: 335-42.
53. Guelrud M, Mendoza S, Rossiter G et al. Effect of local instillation of alcohol on sphincter of Oddi motor activity: combined ERCP and manometry study. Gastrointest Endosc 1991; 37: 428-32.
54. Viceconte G. Effects of ethanol on the sphincter of Oddi: an endoscopic manometric study. Gut 1983; 24: 20-27.
55. Kamm MA, Jordan CC, Leaker BR et al. Pharmacological modulation of gut mucosal and large vessel blood flow. Aliment Pharmacol Ther 2007; 25: 693-702.